(4Z)-2-(3-bromophenyl)-5-hydroxy-4-[(5-nitrofuran-2-yl)methylidene]-2,4-dihydro-3H-pyrazol-3-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: (4Z)-2-(3-bromophenyl)-5-hydroxy-4-[(5-nitrofuran-2-yl)methylidene]-2,4-dihydro-3H-pyrazol-3-one
• 英文别名: (4Z)-1-(3-bromophenyl)-4-[(5-nitrofuran-2-yl)methylidene]pyrazolidine-3,5-dione
• 化学式: C14H8BrN3O5
• 分子量: 378.13
• InChiKey: HKZTXBYJDGFFGR-XFFZJAGNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Inhibitors of ubiquitin E1
  申请人：Weissman Allan M.

  公开号：US20080306130A1

  公开（公告）日：2008-12-11

  The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention.
• INHIBITORS OF UBIQUITIN E1
  申请人：Weissman Allan M.

  公开号：US20100305180A1

  公开（公告）日：2010-12-02

  The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention.
• US8242160B2
  申请人：——

  公开号：US8242160B2

  公开（公告）日：2012-08-14
• [EN] INHIBITORS OF UBIQUITIN E1<br/>[FR] INHIBITEURS DE L'UBIQUITINE E1
  申请人：US GOV HEALTH & HUMAN SERV

  公开号：WO2007059356A2

  公开（公告）日：2007-05-24

  [EN] The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention.
  [FR] La présente invention concerne des composés de pyrazolidinyle, des compositions pharmaceutiques de composés de pyrazolidinyle substitués et des méthodes pour traiter un patient qui est atteint d'un cancer ou d'une infection virale. Cette méthode consiste à administrer à un patient un ou plusieurs des composés de pyrazolidinyle de cette invention.